## List of Figures

Figure No.	Figure Captions	Page No.
2.1.	Schematic representation of P-gp efflux	13
2.2.	P-gp in different organs of the body	15
2.3.	Berberine species	30
2.4.	Berberine species bark	30
2.5.	Berberine chloride (pure form)	31
4.1.	Schematic diagram of nanoprecipitation	55
	method	
4.2.	a. Stainless steel naplet device b. Naplet	60
	disc and c. Uncoated naplet	
5.1.	Standard curve of Berberine	76
5.2.	HPLC Chromatogram of Berberine	77
5.3.	Solubility studies of BBR in different	80
	media	
5.4.	Solubility studies of BBR in different	81
	surfactants in pH 4.5 buffer	
5.5.a.	Contour plot of EE vs stabilizer	87
	concentration (mM) and drug to polymer	
	ratio	
5.5.b.	Response surface plot of EE vs stabilizer	88
	concentration (mM) and drug to polymer	
	ratio	
5.6.a.	Contour plot of PS vs stabilizer	90
	concentration (mM) and drug to polymer	
	ratio	

5.6.b.	Response surface plot of PS vs stabilizer	90
	concentration (mM) and drug to polymer	
	ratio	
5.7.a.	Contour plot of PDI vs stabilizer	91
	concentration (mM) and drug to polymer	
	ratio	
5.7.b.	Response surface plot of PDI vs stabilizer	91
	concentration (mM) and drug to polymer	
	ratio	
5.8	Particle size distribution of (a) BBR-NP	94
	and (b) BBR-SCNP	
5.9.a.	Zeta potential of BBR-NP	94
5.9. b.	Zeta potential of BBR-SCNP	95
5.10.	(a) uncoated naplet (b) enteric coated	95
	naplet	
5.11.	SEM micrographs of (a) BBR-NP	98
	dispersion (b) redispersed nanoparticles	
	from naplet	
5.12.	TEM images of (a) BBR-NP dispersion (b)	99
	redispersed nanoparticles from naplet	
5.13.	FT - IR spectra of (a) pure BBR (b)	102
	physical mixture of BBR and Polymer (c)	
	BBR loaded NP (d) placebo NP prepared	
	in water as a dispersion medium (e)	
	placebo NP prepared in pH phthalate	
	buffer as a dispersion medium	
5.14.	FT-IR spectra of (a) pure BBR (b) PCL (c)	103
	TPGS (d) BBR-SCNP	
5.15.	DSC thermo grams of (a) Pure BBR (b)	104
	PCL (d) BBR-NP	
1	•	i

5.16.	DSC thermograms of (a) Pure BBR (b)	105
	BBR-NP (c) BBR-SCNP	
5.17.	XRD patterns of (a) BBR (b) PCL (C) BBR-	106
	SCNP	
5.18.	TEM images of (a) BBR-NP (b) BBR-SCNP	107
5.19.	In – vitro release study of pure BBR	110
	solution and formulation (F - 6) in PBS	
	medium (pH 7.4)	
5.20.	In-vitro drug release profile of BBR-NP	110
	and BBR-SCNP in PBS medium (pH 7.4)	
5.21.	In-vitro drug release profile of BBR-NP	111
	dispersion and naplet in pH 1.2	
	(hydrochloric acid buffer) and pH6.8	
	(phosphate) medium	
5.22.	Comparative In - vitro release study of	113
	nanoformulation (F-6) in PBS medium	
	(pH 7.4) at "0" and "180" days	
5.23.	TEM images (a) BBR-NP in SBFs (pH 6.8)	118
	(b) BBR-NP in plasma (c) BBR-SC NP in	
	SBFs (pH 6.8) (d) BBR-SCNP in plasma	
5.24.	Standard curve of Berberine in plasma	121
5.25.	Chromatogram of Berberine in plasma	121
5.26.	Results of Plasma concentration – time	123
	curves of single dose pharmacokinetic	
	study	
5.27.	Haemolysis results of BBR-NP, BBR-SCNP	126
	and placebos after incubation in blood	
5.28.	LDH assay results of BBR-NP, BBR-SCNP	127
	and placebos after incubation in blood	
5.29.	Platelet aggregation microscopic images	129

	of drug loaded BBR-NP, BBR-SCNP and placebos NP (45 x)	
5.30.	Platelet count results of BBR-NP, BBR-SCNP and placebos NP after incubation in blood	129
5.31.	Quantification of different Liver enzymes (a) AST (b) ALP (c) ALT	132
5.32.	Quantification of different Kidney enzymes (a) Urea (b) Creatinine	133
5.33.	Microphotograph of intestine of different groups of animals	134
5.34.	Microphotograph of liver of different groups of animals	134
5.35.	Microphotograph of kidney of different groups of animals	135